Health Condition 1: C73- Malignant neoplasm of thyroid gland
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Care Pathway: A structured navigator-assisted rapid care pathway for patients with suspected or confirmed anaplastic thyroid carcinoma involving expedited diagno
Sponsors
Tata Memorial Centre Research Administration Council
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age Greater than or equal to 18 years. 2. New patient with suspected ATC (cytology and biopsy highly suspicious) or histologically confirmed ATC. 3. Presents to HBCHRC for initial evaluation and management. 4. Able to provide informed consent (or proxy consent where allowed).
Exclusion criteria
Exclusion criteria: 1. Already received definitive ATC therapy elsewhere prior to navigator contact. 2. Expected survival less than 48 hours where immediate palliation supersedes study procedures. 3. Declines participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compliance to ATC-RETS To evaluate the effectiveness of ATC-RETS by measuring the proportion of patients who (a) Achieve a multidisciplinary treatment decision within 3 days and (b) Initiate treatment within 5 days of the index diagnostic event. (short delays between diagnosis and treatment allow tumor proliferation, vascular invasion, or airway compromise.)Timepoint: 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| To map the full patient journey from presentation to treatment and identify modifiable workflow delaysTimepoint: 2 years;To assess overall survival (OS) at 3 months and 6 months, and evaluate whether early treatment through ATC-RETS influences short-term survival outcomes.Timepoint: 2 years;To evaluate the uptake and turnaround time of essential molecular testing (including BRAF), and whether results are available in time to inform early treatment decisions.Timepoint: 2 years;To assess the proportion of patients with actionable mutations who initiate appropriate targeted therapy, and document reasons for non-initiation when indicated.Timepoint: 2 years;To identify and categorize barriers to timely care, and describe how navigator interventions address these delays.Timepoint: 2 years;To assess patient and clinician acceptability of the navigator-supported care pathway, using brief structured satisfaction surveysTimepoint: 2 years;Emergency airway intervention rateTimepoint: 2 years;Percentage receiving dabrafenib/trametinib (for BRAF V600E)Timepoint: 2 years;Percentage receiving palliative RTTimepoint: 2 years;Steroid use and acute QOL changes (if feasible)Timepoint: 2 years;Measuring surgery stress score for each patientTimepoint: 2 years | — |
Countries
India
Contacts
Public ContactDr Srinjeeta Garg
Homi Bhabha Cancer Hospital and Research Centre
Outcome results
None listed